Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations

被引:163
作者
Ebben, James P.
Gilbertson, David T.
Foley, Robert N.
Collins, Allan J.
机构
[1] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Minneapolis, MN 55404 USA
[2] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA
[3] Univ Minnesota, Minneapolis, MN USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 1卷 / 06期
关键词
D O I
10.2215/CJN.01110306
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
National payment policies target a hemoglobin range of 11 to 12.5 g/dl for patients with ESRD. However, clinical complications and provider practices may contribute to wide fluctuations over time. This study evaluated the frequency with which patients maintain stable hemoglobin levels below, within, and above the Centers for Medicare & Medicaid Services target range and assessed patterns of hemoglobin level change that resulted in large fluctuations across the target range during a 6-mo period. All hemodialysis patients who survived the first 6 mo of 2003, had Medicare as primary payer, and had Medicare outpatient erythropoietin claims in each of the first 6 mo of 2003 (n = 152,846) were studied. Six patient groups were defined on the basis of patterns of hemoglobin level fluctuation: Consistently low (<11 g/dl), consistently target range (11 to 12.5 g/dl), consistently high (>= 12.5 g/dl), low-amplitude fluctuation with low hemoglobin levels, low-amplitude fluctuation with high hemoglobin levels, and high-amplitude fluctuation. Only 10.3% of patients maintained stable hemoglobin levels during the 6 mo and only 6.5% in the target range. The consistently low group had the highest percentage of hospitalizations and the highest number of comorbid conditions. High-amplitude fluctuation was the most common pattern (39.5%), with hemoglobin levels falling below and rising above the target range during the 6-mo period. Hemoglobin levels in almost 90% of patients are in some degree of flux at any point in time, and the fluctuation is highly associated with clinical complications and provider practices.
引用
收藏
页码:1205 / 1210
页数:6
相关论文
共 7 条
[1]  
Berns Jeffrey S, 2005, Hemodial Int, V9, P255, DOI 10.1111/j.1492-7535.2005.01139.x
[2]   RECOMBINANT HUMAN ERYTHROPOIETIN IN ANEMIC PATIENTS WITH END-STAGE RENAL-DISEASE - RESULTS OF A PHASE-III MULTICENTER CLINICAL-TRIAL [J].
ESCHBACH, JW ;
ABDULHADI, MH ;
BROWNE, JK ;
DELANO, BG ;
DOWNING, MR ;
EGRIE, JC ;
EVANS, RW ;
FRIEDMAN, EA ;
GRABER, SE ;
HALEY, NR ;
KORBET, S ;
KRANTZ, SB ;
LUNDIN, AP ;
NISSENSON, AR ;
OGDEN, DA ;
PAGANINI, EP ;
RADER, B ;
RUTSKY, EA ;
STIVELMAN, J ;
STONE, WJ ;
TESCHAN, P ;
VANSTONE, JC ;
VANWYCK, DB ;
ZUCKERMAN, K ;
ADAMSON, JW .
ANNALS OF INTERNAL MEDICINE, 1989, 111 (12) :992-1000
[3]   Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin [J].
Fishbane, S ;
Berns, JS .
KIDNEY INTERNATIONAL, 2005, 68 (03) :1337-1343
[4]   Intractable anemia among hemodialysis patients: A sign of suboptimal management or a marker of disease? [J].
Kausz, AT ;
Solid, C ;
Pereira, BJG ;
Collins, AJ ;
Peter, WS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (01) :136-147
[5]   Effect of variability in anemia management on hemoglobin outcomes in ESRD [J].
Lacson, E ;
Ofsthun, N ;
Lazarus, JM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (01) :111-124
[6]   Clinical factors associated with achieving K/DOQI hemoglobin targets in hemodialysis patients [J].
Suying Li ;
Robert N. Foley ;
David T. Gilbertson ;
Jiannong Liu ;
Allan J. Collins .
International Urology and Nephrology, 2003, 35 (3) :399-405
[7]  
*NAT KIDN FDN, 1997, AM J KIDNEY DIS S, V30, pS194